What is the treatment approach for patients with pulmonary embolism based on the Pulmonary Embolism Severity Index (PESI) score?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment Approach for Pulmonary Embolism Based on PESI Score

Patients with confirmed pulmonary embolism and low PESI scores (Class I/II or sPESI=0) should be managed as outpatients with direct oral anticoagulants (apixaban or rivaroxaban), provided they meet exclusion criteria, while intermediate and high-risk patients require inpatient management with escalating intensity of monitoring and consideration of reperfusion therapy. 1, 2

Risk Stratification Framework

The PESI score stratifies patients into five classes (I-V) with 30-day mortality rates of ≤1.6% for Class I and 3.6% for Class II, demonstrating excellent discriminatory power. 2, 3 The simplified PESI (sPESI) uses six binary variables, with a score of 0 identifying low-risk patients with 30-day mortality of 1.0-1.1%. 1, 4

Key distinction: While the original PESI classifies more patients as low-risk (40.9% vs 36.8%), both versions have similar sensitivity (90% vs 89%) and negative predictive values (98% vs 97%) for mortality prediction. 3 The sPESI is easier to use clinically and equally powerful for identifying low-risk patients suitable for outpatient management. 1

Treatment Algorithm by Risk Category

Low-Risk PE (PESI Class I/II or sPESI=0)

Outpatient management is appropriate when exclusion criteria are absent. 1, 2, 5

Mandatory exclusion criteria that require inpatient admission: 1, 5

  • Physiologic instability: heart rate >110 bpm, systolic BP <100 mmHg, oxygen saturation <90% on room air, or severe pain requiring opiates
  • Active bleeding or recent major bleeding risk, already on full-dose anticoagulation at time of PE diagnosis
  • Severe renal impairment (eGFR <30 mL/min) or severe liver disease
  • Social factors: inability to return home, inadequate home care, lack of telephone communication, compliance concerns, or patient preference for admission

Anticoagulation for outpatients: 2, 5

  • First-line: Apixaban or rivaroxaban (single-drug regimens without bridging)
  • Alternative: Dabigatran or edoxaban (require initial LMWH bridging)

Critical implementation requirements: 2, 5

  • Same-day anticoagulation initiation before discharge
  • Consultant or senior clinician review before discharge
  • Robust follow-up pathway with access to prompt care if symptoms worsen

Intermediate-Risk PE (PESI Class III or Higher with sPESI ≥1)

These patients require inpatient management with further stratification based on right ventricular dysfunction and cardiac biomarkers. 1, 6

Intermediate-high risk (RV dysfunction on imaging PLUS elevated troponin or NT-proBNP ≥600 ng/L): 1

  • Inpatient monitoring in setting with capability for escalation
  • Standard anticoagulation
  • Close monitoring for clinical deterioration
  • Consider reperfusion therapy if hemodynamic decompensation occurs

Intermediate-low risk (RV dysfunction OR elevated biomarkers, but not both): 1

  • Inpatient management with standard anticoagulation
  • Less intensive monitoring than intermediate-high risk

High-Risk PE (Hemodynamically Unstable)

Defined by sustained hypotension (systolic BP <90 mmHg for >15 minutes), obstructive shock, or cardiac arrest. 1, 6

Treatment: 1, 6

  • Emergency systemic thrombolysis is indicated
  • Intensive care unit admission
  • Hemodynamic support as needed

Important Clinical Nuances

Right heart thrombi represent a critical exception where anatomic location significantly impacts prognosis, with mortality of 21% versus 11% without right heart thrombi, and thrombolytic therapy is the only treatment independently associated with decreased mortality in this subset. 6

Concomitant DVT is an adverse prognostic factor independently associated with 30-day all-cause mortality (OR 1.9,95% CI 1.5-2.4), indicating significant comorbidity. 1

Common Pitfalls to Avoid

Do not rely solely on RV dilation on imaging to exclude patients from outpatient management; if RV dilation is present, measure cardiac biomarkers (BNP/troponin) for additional risk stratification, as normal biomarkers identify low-risk patients even with RV dysfunction. 1, 5

Do not use routine bleeding risk scores beyond the exclusion criteria already outlined for patients deemed low-risk by PESI/sPESI. 5

Do not discharge without same-day anticoagulation - patients must have immediate access to anticoagulation medications before leaving the emergency department. 5

Incidental troponin elevation in low-risk PE patients requires senior review and consideration of alternative causes for troponin release beyond the PE itself. 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Management of Pulmonary Embolism Based on PESI Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Low-Risk Pulmonary Embolism Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Pulmonary Embolism Risk Stratification and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.